Tilray | TRLY - Ebitda

Stock Price
9.26
Daily Change
0.11 1.20%
Monthly
-7.12%
Yearly
1,043.21%
Q2 Forecast
8.92

Tilray reported $8.36M in EBITDA for its fiscal quarter ending in September of 2025.





Ebitda Change Date
Acasti Pharma USD -2.45M 735K Dec/2025
Akebia Therapeutics USD 14.03M 17.19M Mar/2025
Alaunos Therapeutics USD -21.02M 1.33M Mar/2021
Aurora Cannabis CAD 18.48M 3.11M Dec/2025
Avita Medical AUD -9.69M 12.21M Dec/2025
Canopy Growth CAD -2.87M 19.49M Dec/2025
Cronos Group USD 456K 5.22M Dec/2025
Dianthus Therapeutics USD -40.19M 5.36M Sep/2025
Divis Laboratories Ltd INR 8.9B 20M Dec/2025
Ionis Pharmaceuticals USD -157.12M 307.36M Sep/2025
IQVIA Holdings USD 1.05B 97M Dec/2025
Knight Therapeutics CAD 24.45M 3.46M Dec/2025
Moderna USD -790M 582M Dec/2025
Organigram Holdings CAD 5.26M 884K Dec/2025
Organon & Co USD 383M 135M Dec/2025
Revvity USD 248.91M 48.52M Dec/2025
Tectonic Therapeutic USD -21.18M 365K Dec/2025
Tilray USD 8.36M 1.82M Sep/2025
Viatris USD 1B 151.5M Dec/2025
Xeris Pharmaceuticals USD 25.09M 7.67M Dec/2025
Zealand Pharma A/S -727.47M 285.54M Dec/2025